Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population
Anna R Giuliano, Elmar A Joura, Suzanne M Garland, Warner K Huh, Ole-Erik Iversen, Susanne K Kjaer, Alex Ferenczy, Robert J Kurman, Brigitte M Ronnett, Mark H Stoler, Oliver M Bautista, Erin Moeller, Michael Ritter, Christine Shields, Alain Luxembourg
GYNECOLOGIC ONCOLOGY | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2019
OBJECTIVE: Nine-valent human papillomavirus (9vHPV) vaccine efficacy against disease and cervical surgeries related to all nine vaccine components was assessed compared with a historic placebo population. This was not assessed in the 9vHPV vaccine efficacy trial since the trial was quadrivalent HPV (qHPV) vaccine-controlled, efficacy was measured for the five HPV types covered only by 9vHPV vaccine (HPV31/33/45/52/58), but not the four types covered by both vaccines (HPV6/11/16/18). METHODS: Three international, randomized, double-blind studies were conducted using the same methodology. In the 9vHPV vaccine study (NCT00543543), 7106 and 7109 women received 9vHPV or qHPV vaccine, respectively..View full abstract
Funding for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.